(1 - 16 von 16
)
KINAXO Enters Agreement with AstraZeneca
www.b3cnewswire.com
Dr. Henrik Daub, CTO at KINAXO commented: “Posttranslational modifications and their regulation are key factors in understanding cellular behavior and molecular drug action. We are delighted to apply our expertise to ...
Bio M Newsletter Fokus München Neugründungen Kinaxo ...
db.bio-m.org
Dr. Axel Ullrich und Dr. Henrik Daub. Der Schwerpunkt der Aktivitäten liegt auf der Entwicklung von hochspezifischen Kinase-Inhibitoren, die sich durch ein ...
KINAXO Announces European Patent Granted for its Chemical Proteomics...
www.bionity.com
KINAXO Biotechnologies GmbH announced that the European Patent Office has granted a patent entitled “Proteome-wide quantification of small molecule binding to...
"Quantitative Proteomics to Support the Discovery & Development of...
memento.epfl.ch
Date and time, – 15:00 › 16:00. Place and room. SV 1717A. Speaker, Dr. Henrik Daub & Dr. Christian Eckert, Evotec AG, Hamburg, Germany.
KINAXO Announces Agreement with Johnson & Johnson | More ...
pipelinereview.com
· KINAXO is a spin-off from the Max Planck Institute of Biochemistry in Martinsried, initiated by Prof. Dr. Axel Ullrich and Dr. Henrik Daub as well as Max Planck Innovation GmbH, the technology transfer center of the Max Planck Society. KINAXO offers a comprehensive chemical proteomics technology - known as KinaTorTM - to identify and characterize the biological interaction of small …
Kinaxo gets grant for drug-protein interaction technology | Science ...sciencebusiness.net › news › Kinaxo-gets-grant-for-...
sciencebusiness.net
... collaborators, Dr Lothar Jänsch of the Helmholtz Institute in Braunschweig and Dr Henrik Daub of the Max Planck Institute for Biochemistry in Martinsried.
KINAXO Launches Enhanced KinaTor™ Cellular Profiling Service |...
www.technologynetworks.com
The KinaTor™ chemical proteomics platform is tailored for the cellular profiling of kinase inhibitors.
KINAXO Announces European Patent Granted for its Chemical Proteomics...
www.technologynetworks.com
Patent covers technologies exclusively marketed by KINAXO under the trademarks Cellular Target Profiling®, KinAffinity® and Epigenetics Target Profiling™.
Kinaxo Biotechnologies gets European patent for chemical ...www.pharmabiz.com › NewsDetails
www.pharmabiz.com
Such knowledge significantly supports decision-making at various stages of the drug development process” says Henrik Daub, Kinaxo's CTO ...
European Patent Granted for Chemical Proteomics Applications Labmate...
www.labmate-online.com
Such knowledge significantly supports decision-making at various stages of the drug development process,” said Henrik Daub, Kinaxo's CTO and main inventor ...
Mass spectrometric analysis of oxidative protein damage: bayern...
bayern-photonics.de
- and how it may be applied to investigate cellular mechanisms in photodynamic therapy
KINAXO Receives 1M Euro Funding to Quantify Drug Interactions with...
www.technologynetworks.com
The research funding from the German Ministry for Education and Research will enable KINAXO to establish a universally applicable technology platform.
KINAXO launches KinAffinity® services for efficient profiling of...
www.b3cnewswire.com
KinAffinity® provides invaluable information about a kinase inhibitor’s selectivity in a cell or tissue of interest. It simultaneously determines affinities...
Universität Heidelberg - Semper Apertus: Vorträge
www.rzuser.uni-hd.de
Presseinformationen der Universität Heidelberg
KINAXO erhält Seed-Finanzierung und Lizenzrechte für...
www.bionity.com
Die KINAXO Biotechnologies GmbH hat eine Finanzierungsrunde mit dem High-Tech Gründerfonds abgeschlossen. Das Finanzierungsvolumen belief sich auf insgesamt...
sortiert nach Relevanz / Datum